Global Alzheimers Disease Therapeutics Market 2026-2030

Description

The global alzheimers disease therapeutics market is forecasted to grow by USD 6447.5 mn during 2025-2030, accelerating at a CAGR of 10.0% during the forecast period. The report on the global alzheimers disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rapid expansion of aging demographics globally, technological advancements and commercialization of disease-modifying therapies, evolution of blood-based biomarker diagnostics and early intervention screening.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2025
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	9.5%
CAGR	10%
Incremental Value	$6447.5 mn

Technavio's global alzheimers disease therapeutics market is segmented as below:

By Distribution Channel

Hospital pharmacy
Retail pharmacy
E-commerce pharmacy

By Drug Class

Cholinesterase inhibitors
N-methyl-D-aspartate receptor antagonist
Others

By Therapeutic Area

Symptomatic treatments
Disease-modifying therapies
Immunotherapies
Gene therapies
Small molecule inhibitors

Geography

North America
- US
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- The Netherlands
- Spain
Asia
Rest of World (ROW)
Rest of World (ROW)

This study identifies the decentralization of treatment delivery and rise of at-home subcutaneous biologics as one of the prime reasons driving the global alzheimers disease therapeutics market growth during the next few years. Also, strategic convergence of multi-target combinations and non-amyloid modalities and proliferation of digital biomarkers and remote cognitive monitoring infrastructure will lead to sizable demand in the market.

The report on the global alzheimers disease therapeutics market covers the following areas:

Global alzheimers disease therapeutics market sizing
Global alzheimers disease therapeutics market forecast
Global alzheimers disease therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global alzheimers disease therapeutics market vendors that include Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Biogen Inc., Cipla Inc., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., H. Lundbeck AS, Lannett Co Inc., Lupin Ltd., Luye Pharma Group Ltd., Novartis AG, Otsuka Pharmaceutical Co Ltd., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd, Viatris Inc., Zydus Lifesciences Ltd.. Also, the global alzheimers disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR40742

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Therapeutic Area
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
2.3 Factors of disruption
2.4 Impact of drivers and challenges

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Global Alzheimers Disease Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Alzheimers Disease Therapeutics Market 2020 - 2024 ($ million)
5.2 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
5.3 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
5.4 Therapeutic Area segment analysis 2020 - 2024
- Historic Market Size - Therapeutic Area Segment 2020 - 2024 ($ million)
5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 Impact of AI on global Alzheimers disease therapeutics market
6.2 Impact of geopolitical conflicts on global Alzheimers disease therapeutics market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Distribution Channel

8.1 Market segments
8.2 Comparison by Distribution Channel
8.3 Hospital pharmacy - Market size and forecast 2025-2030
8.4 Retail pharmacy - Market size and forecast 2025-2030
8.5 E-commerce pharmacy - Market size and forecast 2025-2030
8.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Drug Class

9.1 Market segments
9.2 Comparison by Drug Class
9.3 Cholinesterase inhibitors - Market size and forecast 2025-2030
9.4 N-methyl-D-aspartate receptor antagonist - Market size and forecast 2025-2030
9.5 Others - Market size and forecast 2025-2030
9.6 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)

10 Market Segmentation by Therapeutic Area

10.1 Market segments
10.2 Comparison by Therapeutic Area
10.3 Symptomatic treatments - Market size and forecast 2025-2030
10.4 Disease-modifying therapies - Market size and forecast 2025-2030
10.5 Immunotherapies - Market size and forecast 2025-2030
10.6 Gene therapies - Market size and forecast 2025-2030
10.7 Small molecule inhibitors - Market size and forecast 2025-2030
10.8 Market opportunity by Therapeutic Area
- Market opportunity by Therapeutic Area ($ million)

11 Customer Landscape

11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

12.1 Geographic segmentation
12.2 Geographic comparison
12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 UK - Market size and forecast 2025-2030
- 12.4.2 Germany - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 The Netherlands - Market size and forecast 2025-2030
- 12.4.6 Spain - Market size and forecast 2025-2030
12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 Japan - Market size and forecast 2025-2030
- 12.5.2 China - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Australia - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

13.1 Market drivers
- Rapid expansion of aging demographics globally
- Technological advancements and commercialization of disease-modifying therapies
- Evolution of blood-based biomarker diagnostics and early intervention screening
13.2 Market challenges
- High clinical trial attrition rates and atrophy of developmental pipelines
- Drastic payer restraints and stringent coverage with evidence development mandates
- Diagnostic infrastructure deficiencies and quality control volatility in biomarker testing
13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
13.4 Market opportunities
- Decentralization of treatment delivery and rise of at-home subcutaneous biologics
- Strategic convergence of multi-target combinations and non-amyloid modalities
- Proliferation of digital biomarkers and remote cognitive monitoring infrastructure

14 Competitive Landscape

14.1 Overview
14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
- Overview on factors of disruption
14.4 Industry risks
- Impact of key risks on business

15 Competitive Analysis

15.1 Companies profiled
- Companies covered
15.2 Company ranking index
- Company ranking index
15.3 Market positioning of companies
- Matrix on companies position and classification
15.4 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- SWOT
15.5 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
15.6 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
15.7 Eisai Co. Ltd.
- Eisai Co. Ltd. - Overview
- Eisai Co. Ltd. - Business segments
- Eisai Co. Ltd. - Key offerings
- Eisai Co. Ltd. - Segment focus
- SWOT
15.8 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
15.9 H. Lundbeck AS
- H. Lundbeck AS - Overview
- H. Lundbeck AS - Product / Service
- H. Lundbeck AS - Key offerings
- SWOT
15.10 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
15.11 Luye Pharma Group Ltd.
- Luye Pharma Group Ltd. - Overview
- Luye Pharma Group Ltd. - Business segments
- Luye Pharma Group Ltd. - Key offerings
- Luye Pharma Group Ltd. - Segment focus
- SWOT
15.12 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
15.13 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Business segments
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- Sun Pharmaceutical Industries - Segment focus
- SWOT
15.14 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
15.15 Torrent Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd. - Overview
- Torrent Pharmaceuticals Ltd. - Product / Service
- Torrent Pharmaceuticals Ltd. - Key offerings
- SWOT
15.16 Unichem Laboratories Ltd
- Unichem Laboratories Ltd - Overview
- Unichem Laboratories Ltd - Product / Service
- Unichem Laboratories Ltd - Key offerings
- SWOT
15.17 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
15.18 Zydus Lifesciences Ltd.
- Zydus Lifesciences Ltd. - Overview
- Zydus Lifesciences Ltd. - Business segments
- Zydus Lifesciences Ltd. - Key news
- Zydus Lifesciences Ltd. - Key offerings
- Zydus Lifesciences Ltd. - Segment focus
- SWOT

16 Appendix

16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
16.3 Currency conversion rates for US$
- Currency conversion rates for US$
16.4 Research methodology
- Research methodology
16.5 Data procurement
- Information sources
16.6 Data validation
- Data validation
16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
16.8 Data synthesis
- Data synthesis
16.9 360 degree market analysis
- 360 degree market analysis
16.10 List of abbreviations
- List of abbreviations